Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP860662.RAAwHcFqYbChJZ5Fwx2Vl0JRREByUJKHcGF_o_YHm0jvA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP860662.RAAwHcFqYbChJZ5Fwx2Vl0JRREByUJKHcGF_o_YHm0jvA130_assertion type Assertion NP860662.RAAwHcFqYbChJZ5Fwx2Vl0JRREByUJKHcGF_o_YHm0jvA130_head.
- NP860662.RAAwHcFqYbChJZ5Fwx2Vl0JRREByUJKHcGF_o_YHm0jvA130_assertion description "[We conducted a phase I study of S-1 combined with irinotecan and oxaliplatin (TIROX) to determine the maximum-tolerated dose (MTD) and recommended dose (RD) and to assess its safety, pharmacokinetics, pharmacogenetics, and preliminary efficacy in patients with metastatic colorectal cancer (MCRC) or metastatic gastric cancer (MGC).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP860662.RAAwHcFqYbChJZ5Fwx2Vl0JRREByUJKHcGF_o_YHm0jvA130_provenance.
- NP860662.RAAwHcFqYbChJZ5Fwx2Vl0JRREByUJKHcGF_o_YHm0jvA130_assertion evidence source_evidence_literature NP860662.RAAwHcFqYbChJZ5Fwx2Vl0JRREByUJKHcGF_o_YHm0jvA130_provenance.
- NP860662.RAAwHcFqYbChJZ5Fwx2Vl0JRREByUJKHcGF_o_YHm0jvA130_assertion SIO_000772 23982118 NP860662.RAAwHcFqYbChJZ5Fwx2Vl0JRREByUJKHcGF_o_YHm0jvA130_provenance.
- NP860662.RAAwHcFqYbChJZ5Fwx2Vl0JRREByUJKHcGF_o_YHm0jvA130_assertion wasDerivedFrom befree-20140225 NP860662.RAAwHcFqYbChJZ5Fwx2Vl0JRREByUJKHcGF_o_YHm0jvA130_provenance.
- NP860662.RAAwHcFqYbChJZ5Fwx2Vl0JRREByUJKHcGF_o_YHm0jvA130_assertion wasGeneratedBy ECO_0000203 NP860662.RAAwHcFqYbChJZ5Fwx2Vl0JRREByUJKHcGF_o_YHm0jvA130_provenance.